Prevention of chronic NSAID induced upper gastrointestinal toxicity.
about
Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesionsLong term proton pump inhibitor (PPI) use and incidence of gastric premalignant lesionsNonsteroidal anti-inflammatory drugs, gastroprotection, and benefit-riskPiroxicam-β-cyclodextrin: a GI safer piroxicamGastrointestinal injury associated with NSAID use: a case study and review of risk factors and preventative strategiesPrimer: managing NSAID-induced ulcer complications--balancing gastrointestinal and cardiovascular risksAcetylsalicylic acid as an adjuvant therapy for schizophreniaA prospective study of aspirin use and the risk of gastrointestinal bleeding in menDendrimer-coupled sonophoresis-mediated transdermal drug-delivery system for diclofenacThe use of H2 antagonists in treating and preventing NSAID-induced mucosal damage.The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review.EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.External validation of a measurement tool to assess systematic reviews (AMSTAR).Cost Effectiveness of Gastroprotection with Proton Pump Inhibitors in Older Low-Dose Acetylsalicylic Acid Users in the Netherlands.Non-Steroidal Anti-Inflammatory Drugs: An Overview of Cardiovascular Risks.Preventive efficacy and safety of rebamipide in nonsteroidal anti-inflammatory drug-induced mucosal toxicityMast cells are critical for protection against peptic ulcers induced by the NSAID piroxicam.The rate of prescribing gastrointestinal prophylaxis with either a proton pump inhibitor or an H2-receptor antagonist in Nova Scotia seniors starting nonsteroidal anti-inflammatory drug therapy.Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcersAdvances in NSAID development: evolution of diclofenac products using pharmaceutical technologyRisk management of risk management: Combining proton pump inhibitors with low-dose aspirinResearch priorities for high-quality geriatric emergency care: medication management, screening, and prevention and functional assessment.Hospital physicians' influence on gastrointestinal protection during treatment with non-steroidal anti-inflammatory drugs and acetylsalicylic acid and the impact on prescribing in primary care.Exacerbation of celecoxib-induced renal injury by concomitant administration of misoprostol in rats.The role of trefoil factor family in apparently healthy subjects administrated gastroprotective agents for the primary prevention of gastrointestinal injuries from low-dose acetylsalicylic acid: a preliminary study.Suppression of contractile activity in the small intestine by indomethacin and omeprazole.PPI versus Histamine H2 Receptor Antagonists for Prevention of Upper Gastrointestinal Injury Associated with Low-Dose Aspirin: Systematic Review and Meta-analysisEP4 Receptor-Associated Protein in Macrophages Ameliorates Colitis and Colitis-Associated Tumorigenesis.The Indications, Applications, and Risks of Proton Pump InhibitorsDUEXIS(®) (ibuprofen 800 mg, famotidine 26.6 mg): a new approach to gastroprotection for patients with chronic pain and inflammation who require treatment with a nonsteroidal anti-inflammatory drug.Gastrointestinal toxicity among patients taking selective COX-2 inhibitors or conventional NSAIDs, alone or combined with proton pump inhibitors: a case-control study.Community-acquired pneumonia and acid-suppressive drugs: position statementCost-effectiveness of nonsteroidal anti-inflammatory drugs and opioids in the treatment of knee osteoarthritis in older patients with multiple comorbidities.Histamine H2 receptor antagonists for decreasing gastrointestinal harms in adults using acetylsalicylic acid: systematic review and meta-analysisBenign Prostatic Hyperplasia and the Risk of Prostate Cancer and Bladder Cancer: A Meta-Analysis of Observational Studies.Nonsteroidal anti-inflammatory drug-induced visible and invisible small intestinal injuryDevelopments in the clinical understanding of osteoarthritis.Managing peptic ulcer and gastroesophageal reflux disease in elderly Chinese patients--focus on esomeprazoleCombination therapy versus celecoxib, a single selective COX-2 agent, to reduce gastrointestinal toxicity in arthritic patients: patient and cost-effectiveness considerations.The use of proton pump inhibitors in treating and preventing NSAID-induced mucosal damage.
P2860
Q24187480-4A9B711F-4AAB-4D37-B327-799A9BD3E04BQ24202377-A0DDF1E6-4AC3-4DB7-AB95-283A3D2D7082Q26864640-678739B8-8492-4B95-BF1D-3DE6509189EBQ27023475-E7ECB17B-2CFA-4CBD-ABC2-49B5EA719AC9Q27026351-B9CEDE9E-1999-4604-B261-8CEC43225AE8Q28200571-0CFF538B-5B5D-4069-B932-1F1B0AAB21DFQ28200931-918A88EC-178F-4C51-90AB-83249726161AQ28743884-5DD5AB0F-6CD9-4764-9324-238D7E3C5A13Q28743884-8F5A800A-915E-43E4-871F-9D997ECA0717Q30406066-78F3A11E-CE9E-424F-939F-935AF6671192Q30415171-73AB27D2-34C2-46F7-BACF-6C85F0A5C22DQ31119957-AE0D29E5-3A1B-4A3A-8B53-1085E4737921Q33292103-48F1C703-CA50-4E63-974B-F9F43FC45277Q33312366-F87D3868-F11F-43B1-972F-4709479099E4Q33611577-0B705667-A120-4A69-BCFD-77F7E0DEE322Q33611577-DF561CBB-9DD3-456A-A1F8-FDAFFB5D1FBDQ33678007-D49F3652-22B9-4DA4-8C86-ADD65308B87CQ33959603-7F7FEFBF-3979-41E1-BF15-1786996EA6AAQ33999952-CC3FBB78-2536-4E4D-9292-05FA41CF597EQ34161152-84121285-DF02-4D31-92EB-7E61DECEA398Q34241978-586F7176-F050-45F5-8B64-36C0DBB76B0BQ34475981-6D127A61-42E5-4083-9A41-F26C332F668EQ35026472-540A82EA-60B4-4E6B-9C43-6A611772C4ADQ35051538-6DCED33D-7C34-460F-8589-59892C6212F4Q35069807-CEC6F406-5E9A-4B77-BF3D-E22287CD4878Q35106649-8F81AC4D-A8F4-453F-9E32-73A4ACFBE71EQ35106649-A8D3A3DB-15E1-4958-AEA6-B2EAC02FE98BQ35209641-53C3AED7-D63B-4899-A39B-7033289390D7Q35573362-95150239-F2FB-4A45-9B4B-1BC16476824CQ35683846-B7F2BA87-4B93-45FF-8471-5E7D7207C778Q35800476-363FF7E3-ED96-46E9-A357-2004801EC370Q36091187-BAD4307F-A113-4B3E-8BAE-2F6504BF9269Q36280849-382202D0-DA2C-4C64-94B4-25D141DDB967Q36280849-49EE14CA-E4AC-466C-87C8-EC3D07FE70DEQ36332697-3ACF10D1-A218-429C-ABD7-F98B5053FCFFQ36332697-73813C5F-DD48-417E-B499-79765129D66AQ36398145-06B0E191-C37E-4499-BD74-28FA6DF95ACEQ36600338-9AEF946B-BE37-4FDD-94AA-27F7459DFBACQ36845550-667122DB-65F2-4389-A463-ACD4C0B28F93Q36891781-AFE940B5-81E0-4F23-93B9-33A79D4C0192
P2860
Prevention of chronic NSAID induced upper gastrointestinal toxicity.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
name
Prevention of NSAID-induced gastroduodenal ulcers.
@nl
Prevention of chronic NSAID induced upper gastrointestinal toxicity.
@ast
Prevention of chronic NSAID induced upper gastrointestinal toxicity.
@en
type
label
Prevention of NSAID-induced gastroduodenal ulcers.
@nl
Prevention of chronic NSAID induced upper gastrointestinal toxicity.
@ast
Prevention of chronic NSAID induced upper gastrointestinal toxicity.
@en
altLabel
Prevention of NSAID-induced gastroduodenal ulcers
@en
Prevention of NSAID-induced gastroduodenal ulcers
@nl
Prevention of NSAID-induced gastroduodenal ulcers.
@ast
Prevention of NSAID-induced gastroduodenal ulcers.
@en
prefLabel
Prevention of NSAID-induced gastroduodenal ulcers.
@nl
Prevention of chronic NSAID induced upper gastrointestinal toxicity.
@ast
Prevention of chronic NSAID induced upper gastrointestinal toxicity.
@en
P1476
P2093
P2860
P698
P1476
Prevention of NSAID-induced gastroduodenal ulcers
@en
Prevention of NSAID-induced gastroduodenal ulcers.
@en
Prevention of chronic NSAID induced upper gastrointestinal toxicity.
@en
P2093
P2860
P304
P356
10.1002/14651858.CD002296
P407
P577
2000-01-01T00:00:00Z
2002-01-01T00:00:00Z